

Birmingham Quality News



2 SEPTEMBER 2024

www.birminghamquality.org.uk

ISSUE: 005

What have we been up to?

• The five centres of the UK NEQAS Clinical Chemistry Division have written a joint document explaining the rationale for our EQA Scheme design.

We would strongly recommend that all Participants read this.



Click QR code for access to document

- The UK NEQAS Clinical Chemistry Division survey is now closed. Thank you to everyone who responded. A summary report will be available soon.
- If you return results via NPEx or plan to use Labgnostic EQA, please note that you are still required to log into the Results and Reports portal for Scheme elements that will not be automated, including any questions. These are part of our Scheme Design and are not optional. Our T&Cs will be updated to reflect this.

Scheme Updates:

- UK NEQAS for Steroid Hormones Distribution 521: Summary of an audit of Testosterone Analysis by Mass Spectrometry
- Robin is back as our patient with AKI (Distribution 212 of the UK NEQAS for Acute and Chronic Kidney Disease Scheme) ... how well controlled is his diabetes this year? See the commentary for Distribution 198 for his last hospital admission.
- It's a KFRE month! If you are calculating KFRE please submit your results at Distribution 212 of the UK NEQAS for Acute and Chronic Kidney Disease Scheme. A summary of the KFRE data from recent KFRE distributions is being presented at a UKKA KFRE meeting in September.

EQA Nuggets:	You may have missed:
Did you know that if you don't have Value, the reason is given in red at bottom of the analyte page	with haemolysis, icterus and lipaemia See commentary on Distribution 185 of
UK NEQAS / Birmingham Quality	Forget to book onto our next webinar nesday 17th September 2024